Section Edited by Jason J. Luke, MD, FACP and Douglas G. McNeel, MD, PhD
Clinical trials: prospective studies including first-in-man clinical trials, phase II/III clinical studies, and immune monitoring investigations. Small, single institution-based retrospective reports are discouraged.
Preclinical studies: studies that lead to mechanistic understanding or novel development of agents and combination therapies directly relevant to human immunotherapy.
Enhancing IgA-mediated neutrophil cytotoxicity against neuroblastoma by CD47 blockadeChilam Chan, Marjolein Stip, Maaike Nederend, Marco Jansen, Elsemieke Passchier, Femke van den Ham, Judith Wienke, Geert van Tetering, Jeanette Leusen
23 May 2024
Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanomaSofie Kirial Mørk, Signe Koggersbøl Skadborg, Benedetta Albieri, Arianna Draghi, Kalijn Bol, Mohammad Kadivar, Marie Christine Wulff Westergaard, Joachim Stoltenborg Granhøj, Annie Borch, Nadia Viborg Petersen, Nikolas Thuesen, Ida Svahn Rasmussen, Lars Vibe Andreasen, Rebecca Bach Dohn, Christina Westmose YdeSee the full list of authors
23 May 2024
Sequence of androgen receptor-targeted vaccination with androgen deprivation therapy affects anti-prostate tumor efficacyAnusha Muralidhar, Melissa Gamat-Huber, Sita Vakkalanka, Douglas G McNeel
20 May 2024
Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validationTamara Gassner, Christina Chittilappilly, Theo Pirich, Benjamin Neuditschko, Klaus Hackner, Judith Lind, Osman Aksoy, Uwe Graichen, Sascha Klee, Franz Herzog, Christoph Wiesner, Peter Errhalt, Martin Pecherstorfer, Klaus Podar, Sonia Vallet
3 May 2024
Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacyDonghwan Jeon, Ethan Hill, Jena E Moseman, Douglas G McNeel
3 May 2024
Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using Y-NM600 in combination with androgen deprivation therapy in murine prostate tumorsAnusha Muralidhar, Reinier Hernandez, Zachary S Morris, Hansel Comas Rojas, Malick Bio Idrissou, Jamey P Weichert, Douglas G McNeel
24 April 2024
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumorsSophia Frentzas, Anna Rachelle Austria Mislang, Charlotte Lemech, Adnan Nagrial, Craig Underhill, Wenjing Wang, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia, Jermaine I G Coward
19 April 2024
Preclinical evaluation of two phylogenetically distant arenavirus vectors for the development of novel immunotherapeutic combination strategies for cancer treatmentJosipa Raguz, Catarina Pinto, Theresa Pölzlbauer, Mohamed Habbeddine, Sandra Rosskopf, Judith Strauß, Valentin Just, Sarah Schmidt, Katell Bidet Huang, Felix Stemeseder, Timo Schippers, Ethan Stewart, Jakub Jez, Pedro Berraondo, Klaus K. OrlingerSee the full list of authors
17 April 2024
Tumor-targeted therapy with BRAF-inhibitor recruits activated dendritic cells to promote tumor immunity in melanomaFlorian Hornsteiner, Janine Vierthaler, Helen Strandt, Antonia Resag, Zhe Fu, Markus Ausserhofer, Christoph H Tripp, Sophie Dieckmann, Markus Kanduth, Kathryn Farrand, Sarah Bregar, Niloofar Nemati, Natascha Hermann-Kleiter, Athanasios Seretis, Sudhir MorlaSee the full list of authors
17 April 2024
Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:CCelia Gomar, Claudia Augusta Di Trani, Angela Bella, Leire Arrizabalaga, Jose Gonzalez-Gomariz, Myriam Fernandez-Sendin, Maite Alvarez, Joan Salvador Russo-Cabrera, Nuria Ardaiz, Fernando Aranda, Timo Schippers, Marisol Quintero, Ignacio Melero, Klaus K Orlinger, Henning LauterbachSee the full list of authors
16 April 2024